Comparative Pharmacology
Head-to-head clinical analysis: BIORPHEN versus TIAGABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIORPHEN versus TIAGABINE HYDROCHLORIDE.
BIORPHEN vs TIAGABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Category C
Category A/B
Anticonvulsant
Anticonvulsant